Stocks
AbbVie Inc.ABBV
NYSEHealthcareBiotechnology$219.68-2.52%
A research-based biopharmaceutical company focused on immunology, oncology, neuroscience, and aesthetics, with blockbuster drugs including Skyrizi and Rinvoq following the U.S. patent expiration of Humira. The company also owns the Botox franchise through its Allergan acquisition, expanding its presence in medical aesthetics and neuroscience. Investors closely monitor its drug pipeline, patent exposure, and cash flow generation, particularly given its large dividend and reliance on a concentrated portfolio of therapies.
Market Cap: $388.4B52W Range: $164.39 – $244.81
Congressional Interest in AbbVie Inc. (ABBV)
13 members of Congress have disclosed 50 trades in AbbVie Inc. (ABBV), a Healthcare company. The buy/sell breakdown shows 22 purchases versus 28 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
50
Unique Politicians
13
Buys
22
Sells
28
Who in Congress Is Trading ABBV?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-09-08 | Lois Frankel | sell | $1K – $15K |
| 2023-09-06 | Rohit Khanna | sell | $15K – $50K |